Epigenetics in urothelial cancer: Pathogenesis, improving diagnostics and developing novel treatment options

Der Urologe. Ausg. A
G NiegischWolfgang A Schulz

Abstract

Urothelial carcinoma of the bladder is a common tumor for which improvements in diagnostic markers and new therapy approaches, in addition to or combined with standard chemotherapy, are urgently required. Epigenetic alterations could provide both novel diagnostic markers and therapeutic targets as they are emerging as crucial factors in the development and progression of this tumor type, likely contributing to altered differentiation and metastatic potential. These alterations affect DNA methylation, histone modifications, chromatin remodeling, long noncoding RNAs, and microRNAs. Factors involved in histone modifications and chromatin remodeling appear to be particularly frequently inactivated by mutations. Thus, histone-modifying enzymes may represent good targets for rational new therapeutic approaches, although thorough investigation of their complex functions is a prerequisite. DNA methylation changes and altered miRNA expression provide promising biomarkers for diagnosis and prognosis that need further validation in comprehensive and well-standardized studies.

References

Mar 17, 2004·Biochimica Et Biophysica Acta·Stéphane AllardJacques Côté
Oct 1, 2008·Cancer Letters·Olaf WittIna Oehme
Sep 3, 2010·PloS One·Carmen J MarsitKarl T Kelsey
Oct 27, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Vera L CostaGuro E Lind
Feb 8, 2011·European Urology·James W F CattoTapio Visakorpi
Jul 27, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas ReinertTorben F Orntoft
Dec 27, 2011·Cancer Letters·Carmen Jerónimo, Rui Henrique
Jan 26, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Marta Sánchez-Carbayo
Jun 19, 2012·Epigenetics : Official Journal of the DNA Methylation Society·Martin LaussMattias Höglund
Dec 5, 2012·Cancer Discovery·Jennifer N Wu, Charles W M Roberts
Mar 19, 2013·Cell·Jeannie T Lee, Marisa S Bartolomei
Apr 26, 2013·Critical Reviews in Oncogenesis·Annika Fendler, Klaus Jung
Aug 6, 2013·Urologic Oncology·Elizabeth A GuancialDavid M Berman
Aug 27, 2013·Epigenetics : Official Journal of the DNA Methylation Society·Ahmad BesaratiniaStella Tommasi
Sep 5, 2013·Cold Spring Harbor Perspectives in Biology·Peter B Becker, Jerry L Workman
Sep 7, 2013·Molecular Cancer·Quanan ZhangJiangdong Wang
Sep 17, 2013·Urologic Oncology·Hana MlcochovaOndrej Slaby
Oct 10, 2013·Nature Reviews. Genetics·Christoph PlassPeter Lichter
Oct 18, 2013·Frontiers in Oncology·Ulrike KreimerWolfgang Goering
Nov 22, 2013·Breast Cancer Research and Treatment·Kristina P SørensenTorben A Kruse
Jan 31, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Mar 4, 2014·Biochimica Et Biophysica Acta·Sarah G Swygert, Craig L Peterson
Mar 13, 2014·Cancer Biology & Therapy·Ren-Chin WuIe-Ming Shih
Mar 13, 2014·Cancer Biology & Therapy·Lorena RosikMichèle Janine Hoffmann
Apr 3, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sheng-Fang SuGangning Liang
Apr 4, 2014·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Hong ChenHongyan Wang
Jun 20, 2014·Oncology Letters·Yi-Ping ZhuYi-Jun Shen
Jul 12, 2014·Journal of Experimental & Clinical Cancer Research : CR·Maria LehmannGünter Niegisch
Jul 18, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ting-Hua YanJin-Hua Jiang
Aug 12, 2014·Epigenomics·Michael T McCabe, Caretha L Creasy
Aug 19, 2014·Nature·Panagiotis NtziachristosIannis Aifantis
Sep 18, 2014·Biological Chemistry·Wolfgang A Schulz
Nov 26, 2014·Methods in Molecular Biology·Wolfgang A SchulzMichèle J Hoffmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Related Papers

Methods in Molecular Biology
Wolfgang A SchulzMichèle J Hoffmann
Nature Reviews. Nephrology
Mitsuo Kato, Rama Natarajan
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus
S-Q LiX-F Cao
Methods in Molecular Biology
Mingzhou Guo, Wenji Yan
Biomarkers in Medicine
Leonel Maldonado, Mohammad Obaidul Hoque
© 2021 Meta ULC. All rights reserved